Adjunct Professor in Medicine-Hematology/Oncology, Northwestern University Medical School
Oncology
Dr. Gershon Y. Locker, MD
Dr. Gershon Y. Locker works in the field of Oncology. He studied medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. Doctor Gershon Y. Locker, MD is a published doctor and has 58 publications published. The lastest was: 'NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network.'
Publications
- Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
- The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features.
- Gastric Cancer Clinical Practice Guidelines.
- Esophageal Cancer Clinical Practice Guidelines.
- Oxaliplatin-related acute myelogenous leukemia.
- Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
- Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
- Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
- Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.
- Clinical therapy and HER-2 oncogene amplification in breast cancer: chemo- vs radiotherapy.
- Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
- Tetrasomy 8 in acute monoblastic leukemia (AML-M5a) with myelosarcomatosis of the skin.
- Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).
- Adjuvant vaccination in colorectal carcinoma.
- Cutaneous reactions to GM-CSF in inflammatory breast cancer.
- Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients.
- ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
- Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system persp...
- Cancer in Jews: introduction and overview.
- Genetic factors and colorectal cancer in Ashkenazi Jews.
- Inflammatory bowel disease in Ashkenazi Jews: implications for familial colorectal cancer.
- Breast surgery in the ''Arimidex, Tamoxifen Alone or in Combination'' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastec...
- 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
- The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer.
- Elevated serum CA 125 secondary to tuberculous peritonitis.
- Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
- Antineoplastic drugs: clinical pharmacology and therapeutic use.
- Experimental animal models of adriamycin cardiotoxicity.
- The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature.
- Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.
- Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.
- The effect of doxorubicin on hepatic and cardiac glutathione.
- Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial.
- Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
- Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
- Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial.
- Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.
- Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film.
- Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.
- Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
- Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
- High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial.
- Hodgkin's disease and HIV infection.
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'' adjuvant treatment for breast cancer.
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
- Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years'' adjuvant treatment for early b...
- Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
- Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
- Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.
- Adjuvant use of anastrozole in breast cancer.
- A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.
- NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network.
- Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysi...
- Effect of interferon therapy on indomethacin-sensitive immunoregulation in the peripheral blood mononuclear cells of renal cell carcinoma patients.
- Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administrat...
- Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer.
Schools
Harvard Medical School
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Cigna
- Medicare MCR
Education
-
University of Chicago -
Harvard Medical School
Helpful Reviews
Similar Doctors
|
Ticiana D. Leal
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret C. Telfer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Thirman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary R. MacVicar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sigmund A. Weitzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Maitland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randy F. Sweis, MD
This Doctor is OpenDoctor Recommended.
|